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Abstract
A variety of approaches have been employed to generate binding proteins from non-antibody scaffolds. Utilizing a beta-
sheet of the human ubiquitin for paratope creation we obtained binding proteins against tumor necrosis factor (TNF)-alpha.
The bioactive form of this validated pharmacological target protein is a non-covalently linked homo-trimer. This structural
feature leads to the observation of a certain heterogeneity concerning the binding mode of TNF-alpha binding molecules,
for instance in terms of monomer/trimer specificity. We analyzed a ubiquitin-based TNF-alpha binder, selected by ribosome
display, with a particular focus on its mode of interaction. Using enzyme-linked immunosorbent assays, specific binding to
TNF-alpha with nanomolar affinity was observed. In isothermal titration calorimetry we obtained comparable results
regarding the affinity and detected an exothermic reaction with one ubiquitin-derived binding molecule binding one TNF-
alpha trimer. Using NMR spectroscopy and other analytical methods the 1:3 stoichiometry could be confirmed. Detailed
binding analysis showed that the interaction is affected by the detergent Tween-20. Previously, this phenomenon was
reported only for one other type of alternative scaffold-derived binding proteins – designed ankyrin repeat proteins –
without further investigation. As demonstrated by size exclusion chromatography and NMR spectroscopy, the presence of
the detergent increases the association rate significantly. Since the special architecture of TNF-alpha is known to be
modulated by detergents, the access to the recognized epitope is indicated to be restricted by conformational transitions
within the target protein. Our results suggest that the ubiquitin-derived binding protein targets a new epitope on TNF-
alpha, which differs from the epitopes recognized by TNF-alpha neutralizing antibodies.
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Introduction
The use of antibodies dominated the development of molecules
with specific binding properties in the past decades. However, they
show particular limitations arising mainly from their architecture.
The composition of full-size antibodies from four polypeptide
chains (two heavy and two light chains) that are connected by
inter-chain disulfide bonds demands complicated cloning steps and
a production using secretory pathways. The large molecular size of
complete antibodies limits penetration of dense tissue, reducing
applicability in e.g. solid tumor therapy. By using the Fv fragment,
containing the whole antigen binding site of an antibody, the
molecule size can be reduced. However, reduced stability of Fv
fragments requires the employment of protein engineering to
obtain suitable molecules for biotechnological and medical
applications [1].
As a complement to antibodies, alternative scaffold proteins
were utilized to develop molecules with the desired properties
regarding binding, architecture and stability [2–6]. Almost all of
these scaffolds consist of a single polypeptide chain and lack
intrinsic cysteines, offering the possibility for intracellular expres-
sion in bacteria. A high thermodynamic stability gives the
opportunity of creating a binding surface by extensive substitution
of amino acids without disturbing the overall fold of the protein or
its solubility. Furthermore, most of the scaffold proteins are chosen
to be small protein molecules with a molecular weight of less than
15 kDa. Different alternative scaffolds were successfully used to
create artificial binding proteins against a number of target
molecules from various classes. Affinities comparable to antibod-
ies, down to the picomolar range, were obtained e.g. for
tetranectins, anticalins, DARPins and affibodies [4,7–9]. The
diversity of the scaffolds almost coincides with the number of
approaches to create a target specific binding area in terms of
localization and method of amino acid substitution. Often, but not
necessarily, amino acid positions known to be involved in natural
interactions of the scaffold are used as a starting point for the
generation of tailored binding properties, for example in the
lipocalin-derived anticalins and the affibodies [5,7]. In analogy to
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engineering of these potential paratopes by creating diverse
libraries with subsequent selection by evolutionary methods yields
target-binding protein variants.
In the context of the particular scaffold, the selection of the
amino acid positions to be involved in paratope formation offers
the possibility to influence the epitope selectivity and the
thermodynamic parameters. By employing particular secondary
structures for creation of the paratope, its rigidity and thus the
entropic effects on binding can be affected. The loops that are
mediating the binding properties in antibodies and several
scaffolds often show structural rearrangements upon target
interaction. Fixation of mobile loops during the binding event
results in unfavorable entropic contributions. A higher initial
complementarity of the paratope with the epitope geometry,
together with a diminished intrinsic flexibility, permits reduction of
entropic losses, though on the risk of reducing variability in target
binding. Indeed, examples of antibodies after affinity maturation
show a decrease in entropic costs for complex association, resulting
from structural pre-organization of the binding site [10].
Consequently, harnessing rigid secondary structures of an
alternative scaffold should in principle reduce negative entropic
effects.
Such an approach to generate a universal binding site upon
rigid secondary structures uses the helices of staphylococcal
protein A for paratope creation. Furthermore, the beta-sheet
structures of human gammaB-crystallin and human ubiquitin were
employed to create de novo binding sites [11,12]. In contrast to the
de novo generation of such a paratope, in this work the knowledge
on the well-characterized binding site in the ubiquitin for the
ubiquitin-binding domains (UBD) should be used for creation of a
new ubiquitin variant library. This binding area is located at a
hydrophobic patch comprising L8, I44 and V70 [13,14]. The
dissociation constants, reported for most of the UBDs, range from
micro- to millimolar values [15,16]. Using these amino acid
positions as a starting point for the paratope generation, we aimed
to create ubiquitin-based binders with higher affinities, at least in
the nanomolar range.
For validation of the feasibility of this strategy to generate
binders from the scaffold ubiquitin, the tumor necrosis factor
(TNF)-alpha was chosen as a target protein. The cytokine TNF-
alpha was originally discovered by its activity of killing tumor cells
in vitro. Today it is a well established pharmacological target for the
treatment of inflammatory diseases, e.g. rheumatoid arthritis and
Crohn’s disease. Currently, etanercept, the TNF-receptor 2
dimerized by fusion to the IgG1 Fc fragment, and two monoclonal
antibodies, i.e. infliximab and adalimumab, are approved TNF-
inhibiting biologicals [17]. Besides efforts to create TNF-inhibiting
antibodies, various attempts of selection with alternative scaffolds
were made against this protein. To compete with the TNF-
receptor for binding to TNF-alpha, the biologically active TNF-
inhibitors need extraordinary high affinities. Typically, dissocia-
tion constants in the subnanomolar range are required [4,17]. The
homotrimeric structure of the cytokine leads to the observation of
certain heterogeneity concerning the oligomer/monomer-specific-
ity of TNF-alpha binders. For example, etanercept recognizes only
the homotrimer form of TNF-alpha. It binds to an epitope which
involves two subunits simultaneously [18]. In contrast, most TNF-
alpha neutralizing monoclonal antibodies, binding only one
subunit, recognize also the monomeric form [17,19,20].
In the present study we show a detailed molecular character-
ization of an artificial binding protein, selected in vitro from a
ubiquitin F45W-derived library against TNF-alpha. To examine
the ubiquitin variant-TNF-alpha interaction, including the effect
of the detergent Tween-20, several methods such as ELISA,
isothermal titration calorimetry and NMR spectroscopy were
utilized. Additionally, biophysical parameters of the selected
binder were evaluated by spectroscopic methods. We find that
the ubiquitin variant binds specifically the trimer form of the target
molecule TNF-alpha with submicromolar affinity. The epitope
accessibility can be enhanced by the detergent Tween-20, an
observation according to our knowledge never reported for TNF-
alpha binding antibodies before.
Materials and Methods
Materials
All chemicals and culture media were obtained from Roth
(Karlsruhe, Germany), Merck (Darmstadt, Germany) and Appli-
chem (Darmstadt, Germany) unless stated otherwise. DNA
modifying enzymes were obtained from Fermentas (Roth, Ger-
many). Chromatography materials and devices were from GE
Healthcare (Uppsala, Sweden).
Production, purification and chemical modification of
TNF-alpha
The target protein TNF-alpha was produced by SUMO-fusion
strategy as published previously [21]. The product identity was
confirmed by mass spectrometry. An L929 cell assay was
performed to compare the biological activity with commercially
available TNF-alpha.
For chemical labeling of the TNF-alpha, Sulfo-NHS-LC-biotin
(Pierce Biotechnology, Rockford, IL) was used. To obtain
preferentially N-terminally labeled proteins reactions were per-
formed at pH 6.5. Further reaction conditions were kept
according to manufacturer’s instructions. Successful modification
was confirmed by mass spectrometry.
To avoid confusion the concentration of TNF-alpha is given per
monomer for all experiments in this manuscript.
Library construction, selection and binding variant
identification
As scaffold basis a ubiquitin variant with an F45W substitution
was used to allow routine spectroscopic characterization without
relinquishing the positive properties of ubiquitin, particularly in
terms of stability [22]. For the ubiquitin library generation, six
amino acid positions of the scaffold were selected for randomiza-
tion based on an analysis of involvement in natural interactions of
ubiquitin [13], in silico algorithms calculating the stability effects of
amino acid substitutions [12], and visual inspection using the open
source software PyMOL version 0.99rc6 (DeLano Scientific LLC,
South San Francisco, CA). Subsequently, overlapping oligonucle-
otides containing NNK motifs at the randomized positions were
used for PCR-based library construction. With the resulting DNA
library six selection cycles of ribosome display were performed
[23,24]. The isolated cDNA from the last selection cycle was
subcloned into a modified pET-20b vector. After transformation
of the ligation product into Escherichia coli (E. coli) NovaBlue(DE3),
192 clones were cultivated for 20 h at 37uC in 96-deep well format
using 400 ml auto-induction medium ZYM-5052 [25]. The cells
were harvested by centrifugation for 10 min at 40006 g.
Subsequently, the pellets were resuspended in PBS (137 mM
NaCl, 8 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4 pH 7.4)
supplemented with 200 mgm l
21 lysozyme and BugBuster (Nova-
gen, Darmstadt, Germany) and incubated for 10 min at 25uC.
The lysate was cleared by centrifugation for 30 min at 50006 g
and the supernatant was diluted ten-fold for use in ELISA. Binding
of the ubiquitin variants to the target TNF-alpha and to lysozyme
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peroxidase conjugate (Sigma-Aldrich, St. Louis, MO). The target-
binding variant with the highest binding signal, termed 10F, was
chosen for further characterization. For this purpose, the genes of
human ubiquitin F45W (optimized for expression in E. coli;
GENEART, Regensburg, Germany) and the variant 10F (without
Flag-tag) were subcloned into a modified vector pET-20b. The
coding sequence of 10FDY was obtained by inserting the codons
for the amino acids D58 and Y59 into the 10F gene by standard-
PCR methods and was subcloned into pET-41b (Novagen,
Darmstadt, Germany).
Production and purification of ubiquitin variants
For purification, ubiquitin F45W and its variants were produced
in E. coli BL21(DE3) using auto-induction media ZYM-5052 for
unlabeled proteins or N-5052 containing
15NH4Cl (Sigma-
Aldrich, St. Louis, MO) for
15N-labeled proteins, respectively
[25]. Following incubation for 20 h at 37uC and 220 rpm, cells
were harvested, resuspended in NPI-20 (20 mM Na2HPO4,
150 mM NaCl, 20 mM imidazole pH 8.0) and disrupted as
described previously [21]. The lysate was cleared by centrifugation
and the supernatant was applied on an A ¨ktaXpress system to a 5-
ml HisTrap HP column equilibrated with buffer NPI-20. After a
washing step comprising 7 column volumes of NPI-40 (NPI-20,
but 40 mM imidazole), the target protein was obtained by elution
using NPI-500 (NPI-20, but 500 mM imidazole). Protein-contain-
ing fractions from the elution step were loaded on a HiLoad 16/60
Superdex 75 pg column for size exclusion chromatography using
PBS, including 1 mM EDTA pH 7.4, as running buffer at a flow-
rate of 1.0 ml min
21.
ELISA
The immobilization was performed by overnight incubation at
4uCw i t h5 0mlw e l l
21 antigen in PBS on Maxisorp plates (Nunc,
Wiesbaden, Germany). Then wells were blocked with 300 ml
PBS, 1% (w/v) BSA for 2 h at 37uC. Each of the following
incubation steps was preceded by three times washing with
300 ml PBS supplemented with 0.05% (v/v) Tween-20
(PBST0.05). His6-tagged or biotinylated proteins were allowed
to bind to immobilized target for up to 2 h. For competition
ELISA, the proteins were incubated with competitor at least 1 h
before (on ice) and during the binding reaction. Bound protein
was detected by anti-His6-mAB-peroxidase conjugate (Roche
Applied Science, Mannheim, Germany) or avidin-peroxidase
conjugate (Pierce Biotechnology, Rockford, IL) diluted in
PBST0.05 using TMB Plus (Kem-En-Tec Diagnostics, Taastrup,
Denmark) as substrate.
Isothermal titration calorimetry
TNF-alpha and the ubiquitin variant 10F were dialyzed
exhaustively against PBS, 0.5 mM EDTA pH 7.4 and subse-
quently supplemented with Tween-20 to a final concentration of
0.05% (v/v). Isothermal titration calorimetry was performed using
a MicroCal VP-ITC titration microcalorimeter (MicroCal Inc.,
Northampton, MA) at 25uC. A series of 10-ml injections of 10F
(135 mM) were added sequentially into TNF-alpha (35.6 mM). The
heats of dilution for injecting 10F into measurement buffer were
subtracted from binding experiments before curve fitting.
Analytical size exclusion chromatography
TNF-alpha and the ubiquitin variant 10F were prepared in
running buffer (PBS, 1 mM EDTA pH 7.4, supplemented with
0.05% (v/v) Tween-20 if necessary) to analyze the complex
formation. Aliquots were loaded on a Superose 12 10/300 GL
column at a flow-rate of 0.6 ml min
21.
NMR spectroscopy
All NMR experiments were carried out on a Bruker 600 Avance
III spectrometer equipped with a 5 mm triple inverse probehead
for TNF-alpha titration experiments to 10F and on a Bruker 800
Avance III spectrometer equipped with a 5 mm triple inverse
cryoprobe for recording free state
1H-
15N fHSQC spectra [26] of
ubiquitin F45W, 10F and 10FDY. Spectra were measured in PBS,
1 mM EDTA pH 7.4, containing 10% (v/v) D2Oa t2 5 uC.
The NMR titration of TNF-alpha to the
15N-labeled ubiquitin
variant 10F was performed under equilibrium conditions in the
presence and in the absence of 0.05% (v/v) Tween-20. For every
step during the titration we followed the peak intensity and the
chemical shift value of every 10F resonance in a series of
1H-
15N
fHSQC spectra of the
15N-labeled 10F. All NMR spectra were
processed using NMRPipe [27] and analyzed using NMRView
[28]. We ended up with a 12-fold excess for both titration
experiments of TNF-alpha to 10F (1890 mM TNF-alpha, 160 mM
10F). As the particular chemical shift value for every cross peak
representing the free state of 10F did not change during the whole
titration experiment but the particular peak intensity decreases,
the slow NMR chemical exchange limit between free and TNF-
alpha-bound state of 10F was assumed for data analysis. Every
amide proton intensity was dilution corrected for quantitative data
analysis.
Far-UV circular dichroism spectroscopy
To analyze the secondary structure of the ubiquitin variants,
far-UV circular dichroism (CD) experiments were performed on a
Jasco J-810 spectropolarimeter (Jasco Inc., Easton, MD, USA) at
25uC in a 1 mm quartz cuvette for native samples or 0.1 mm for
guanidine hydrochloride denatured samples. Measurements
ranged from 185 to 260 nm at a scanning rate of 10 nm min
21
and a bandwidth of 1 nm. All spectra were accumulated 20 times
with a response time of 4 s. For recording spectra of the natively
folded proteins concentrations of 7.01 mM for 10F, 10.16 mM for
ubiquitin F45W, and 8.25 mM for 10FDY in 10 mM KH2PO4
pH 7.4, respectively, were used. Measurements for protein
samples denatured in 6 M guanidine hydrochloride were per-
formed with 62.0 mM 10F and 32.5 mM ubiquitin F45W. The
buffer-corrected spectra were converted to mean residue ellipticity
according to Schmid [29].
Further methods are described in Methods S1.
Results
Selection and identification of TNF-alpha binding
ubiquitin variants
Several considerations influenced the construction of the
ubiquitin F45W-based library. First, as the basis for a paratope
with new binding properties amino acid residues in the beta-sheet
involved in natural interactions with ubiquitin-binding proteins
were identified by thorough literature analysis on ubiquitin
complexes as well as functional sequence alignments of ubiqui-
tin-like proteins. Furthermore, tolerance of selected positions
against random substitution was deduced by in silico algorithms
[12]. Finally, by additional visual inspection of the 3D-model of
ubiquitin (pdb-code 1UBI) using PyMOL software the six amino
acid residues K6, L8, R42, I44, H68 and V70 were chosen for
randomization (Fig. 1). These residues are located in the beta-sheet
and form a contiguous surface area of approximately 475 A ˚ 2.
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by PCR-based gene synthesis with degenerated oligodeoxynucleo-
tides to introduce randomized codons at the six selected positions.
The TNF-alpha binding ubiquitin variant characterized in this
work was isolated from this library using ribosome display
selection. Although the naı ¨ve library comprised only six random-
ized amino acid positions (Fig. 1) the variant analyzed here in
detail showed altogether nine modifications. In addition to the six
expected substitutions at the randomized amino acid positions
(K6F, L8Y, R42A, I44E, H68P, V70F), the exchange K29R,
located in helix 1 of ubiquitin, as well as the deletion of D58 and
Y59 in the loop, leading into the last beta-strand, were found.
Since the deletions were assumed to have a major impact on
structure and stability of the ubiquitin variant the two amino acids
were re-inserted resulting in the variant 10FDY. For further
experiments 10F, 10FDY and ubiquitin F45W were produced as
His6-tagged proteins in Escherichia coli BL21(DE3) and purified via
IMAC and a subsequent size-exclusion chromatography step.
Binding characterization by ELISA methods
All binding studies were performed in the presence of 0.05% (v/
v) Tween-20 because the detergent was present in the primary
selection as well. In ELISA studies only the ubiquitin variant 10F
was able to bind, but not 10FDY nor ubiquitin F45W (Fig. S1).
Furthermore, ELISA experiments confirmed that 10F binds
specifically to human TNF-alpha and shows no interaction with
other proteins sharing up to 80% sequence similarity (Fig. 2A).
In a competition ELISA we were able to inhibit the binding of
biotinylated TNF-alpha to immobilized variant 10F with etaner-
cept (TNF receptor-IgG1-Fc-part fusion) and with the variant 10F
itself (Fig. 2B). A similar ELISA setup was used to obtain
information on the affinity of the ubiquitin variant. Binding of 10F
to immobilized TNF-alpha was competed by different concentra-
tions of soluble TNF-alpha resulting in an IC50-value of
0.2960.05 mM (Fig. 2C).
Characterization of complex formation and stoichiometry
To characterize the thermodynamics of the interaction of 10F
and TNF-alpha isothermal titration calorimetry experiments were
performed. Comparable to the IC50-value obtained in ELISA, a
KD value of 0.1860.05 mM was observed (Fig. 3). The 10F
molecule was bound in an exothermic, enthalpy driven reaction
(DH=257.362.5 kJ mol
21;T DS=218.863.2 kJ mol
21) with
one 10F molecule binding to one TNF-alpha trimer (N=
0.3560.04).
Binding analysis between TNF-alpha and the ubiquitin variant
10F was followed on a residue-by-residue basis using NMR
spectroscopy. A series of
1H-
15N fHSQC spectra of the 10F
variant with increasing amounts of TNF-alpha was recorded (in
presence of 0.05% (v/v) Tween-20). Almost all chemical shift
positions seen for the free 10F had changed to new values in the
complex state (Fig. S2A). Acquisition of one 2D correlation
spectrum of
15N-labeled 10F immediately after each addition of
TNF-alpha, showed a linear decrease of essentially each individual
cross peak representing the free state of the 10F variant until a
stoichiometry of three TNF-alpha subunits per 10F monomer
(Fig. 4). The repetition of the titration experiment in absence of
Tween-20 led neither to shifting of any amide resonance nor to
additional NMR signals of the TNF-alpha-bound state of 10F,
even until the final titration step. This suggested that during the
individual NMR titration steps the binding equilibrium had not
been reached. Surprisingly, an incubation time for the final
complex solution of 12 h leads to a complete population of the
TNF-alpha-bound state of the 10F variant. Both
1H-
15N spectra
representing the complex state (the 12 h-incubated complex in
absence of detergent and the 0.05% (v/v) Tween-20 containing
final state) are fully superimposable (data not shown).
The complex stoichiometry was validated by equilibrium
sedimentation (analytical ultracentrifugation) of fluorescein-labeled
10F (Fig. S3). Using absorbance measurement at 490 nm allowing
specific detection of the fluorescein labeled ubiquitin variant, a
molecular mass of 1161 kDa was found for 10F (calculated mass
10 kDa) in absence of TNF-alpha. Upon addition of an excess of
TNF-alpha the molecular mass shifted to 6565 kDa correspond-
ing to the calculated molecular mass of the TNF-alpha trimer-10F
complex (62 kDa). A fluorescence homoquenching assay [30] was
used to follow the monomer exchange between TNF-alpha trimers
in presence and absence of TNF-alpha binding molecules (Fig. S4).
Complex formation of TNF-alpha with binding partners recog-
nizing the trimeric species by binding several subunits simulta-
neously should have a stabilizing effect, thus decreasing the
monomer exchange rate. Indeed, upon addition of etanercept,
known to bind the trimer form of TNF-alpha, an almost complete
inhibition of the exchange was observed. The ubiquitin variant
10F decreased the exchange rate significantly as well, but not
completely. In contrast, after addition of the variant 10FDY,
Figure 1. Amino acid positions chosen for randomization in
library construction. Based on the scaffold ubiquitin (shown here in
cartoon representation), in particular with an F45W substitution, a
library for the selection of artificial binding proteins was generated. For
this purpose the six surface-exposed amino acid residues K6, L8, R42,
I44, H68 and V70 (highlighted in red), located in the beta-sheet region
of the scaffold, were chosen to be randomized for library construction.
After in vitro selection against TNF-alpha, in the ubiquitin variant named
10F the residues D58 and Y59 (highlighted in blue) were found deleted.
This figure was generated using pdb entry 1UBI and the software
PyMOL version 0.99rc6 (DeLano Scientific LLC, South San Francisco, CA).
doi:10.1371/journal.pone.0031298.g001
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increase was unaltered compared to the buffer control.
To verify the results on the Tween-20 dependence of the
interaction observed in the NMR experiments, size-exclusion
chromatography experiments were conducted. To show complex
Figure 2. ELISA analysis of the TNF-alpha binding ubiquitin
variant 10F. (A) Specificity of ubiquitin variant 10F. The interaction of
the purified, His6-tagged binder with different immobilized target
proteins (500 ng per well, human serum was used without dilution) is
shown. (NGF: nerve growth factor, nPAC-1Rs: short splice form of N-
terminal domain of human PACAP-receptor 1) (B) Characterization of
the specificity by competition of the interaction of TNF-alpha and 10F.
Biotinylated TNF-alpha (1 mM), preincubated for 1 h with competitor
(etanercept: TNF-receptor 2 dimerized by fusion to IgG Fc), was
incubated with immobilized 10F (100 ng per well). Detection by avidin-
peroxidase demonstrates competition by etanercept. (C) Concentra-
tion-dependent competition ELISA. 10F (100 nM, His6-tagged), prein-
cubated with different concentrations of TNF-alpha, was incubated with
immobilized TNF-alpha (150 ng per well). An IC50 value of 289653 nM
was determined.
doi:10.1371/journal.pone.0031298.g002
Figure 3. Isothermal titration calorimetry of TNF-alpha and the
ubiquitin variant 10F. 10F at 135 mM was injected into the
measurement cell containing TNF-alpha at 35.6 mM. The titration was
carried out at 25uC. Experiments were conducted in duplicate. The
upper panel shows the raw data and the lower panel shows the
integrated enthalpy data corrected for dilution heat of a single
experiment. Fitting the data to a single-site binding model (solid line),
we determined KD=180650 nM, stoichiometry factor N=0.3560.04,
DH=257.362.5 kJ mol
21 and TDS=218.863.2 kJ mol
21.
doi:10.1371/journal.pone.0031298.g003
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ubiquitin variant 10F or a mixture of both, respectively, were
loaded onto an analytical gel filtration column. In presence of the
detergent Tween-20, 10 min of incubation were sufficient for
complete formation of the complex (Fig. 5A). By analogy with the
NMR measurements, in the absence of Tween-20 binding of
unlabeled 10F by TNF-alpha occurred only in the time-range of
hours (Fig. 5B). Corresponding to the peak area decrease of 10F,
SDS-PAGE analysis of the SEC fractions confirmed the co-elution
of 10F in the TNF-alpha peak upon prolonged incubation
(Fig. 5C).
Structural information on the ubiquitin variant 10F
Due to the substitution of 12% of the original sequence of the
scaffold ubiquitin F45W in the selected variant 10F the overall
structure of the protein might be affected. To investigate this,
structural information on the selected binder was obtained. For
secondary structure analysis of ubiquitin F45W and its two
variants 10F and 10FDY far-UV circular dichroism (CD)
spectroscopy was used. All three proteins showed a negative band
at 20761 nm with the same intensity for ubiquitin F45W and
10FDY but approximately 70% higher intensity for 10F (Fig. 6). A
shoulder at 222 nm was observed for all proteins although less
pronounced for 10FDY. Furthermore, a positive band was
observed at 192 nm for ubiquitin F45W, 187 nm for 10F and
190 nm for 10FDY. After unfolding of ubiquitin F45W and 10F in
6 M guanidine hydrochloride, identical spectra were obtained for
both proteins. The differences in the CD spectra of all three
proteins suggest that especially the TNF-binding 10F may possess
an altered structure compared to ubiquitin F45W. However, a
detailed interpretation of these spectral differences is difficult
because changes in the number of aromatic amino acids or their
environment between the different proteins may significantly
influence the far-UV CD spectra.
Far-UV CD spectroscopy was also employed to follow thermal
un- and refolding of 10F. Measurements at 200 nm showed
transition midpoints for unfolding at 75.960.2uC and for refolding
at 72.460.2uC (Fig. S5). 10FDY and ubiquitin F45W did not
unfold completely under the experimental conditions. Far-UV CD
spectra of 10F recorded before and after two cycles of heating to
90uC and cooling to 20uC showed no differences in shape or
intensity (data not shown). Together, a reversible heat induced
unfolding transition can be concluded. Probing the tertiary
structure of 10F and 10FDY by tryptophan fluorescence, thermal
denaturation experiments resulted in Tm values of 69.060.1uC
(10F) and 81.160.2uC (10FDY) (data not shown). Due to
incomplete denaturation no Tm value was obtained for ubiquitin
F45W.
A more qualitative information about the overall protein fold
for the scaffold protein ubiquitin F45W and the two variants 10F
and 10FDY was obtained from
1H-
15N fHSQC spectra.
15N-
labeled proteins were produced in auto-induction medium N-5052
[25] and purified using the identical procedure as for the unlabeled
proteins.
1H-
15N fHSQC spectra of all three proteins, each
showing well dispersed cross peaks with narrow line shapes (Fig. 7,
Fig. S2), indicate fully folded proteins with pronounced secondary
and tertiary structure elements. A cross peak assignment for the
scaffold ubiquitin F45W was performed on the basis of reported
values for the ubiquitin wildtype [31–33]. Although the two
variants 10F and 10FDY showed well dispersed
1H-
15N correlation
spectra, their individual chemical shift positions differ clearly
compared to the resonances for the scaffold protein. Due to this
the peak assignment of the ubiquitin F45W spectrum could not be
transferred to the spectrum of 10F. Consequently, structure
determination of 10F in its soluted state as well as bound to TNF-
alpha requires a completely new peak assignment. Even so, the
spectral comparison suggests subtle differences of the tertiary
structure between the scaffold protein and the two variants 10F
and 10FDY.
Discussion
To overcome the limitations of antibodies, which restrict their
use for several biotechnological and pharmaceutical applications,
artificial binding proteins based on alternative scaffolds were
proven to be a valuable concept. Besides showing advantageous
properties regarding architecture, stability and production [2],
these alternative scaffolds offer the possibility to target epitopes
that are not accessible for antibodies. The large size of the
framework of antibodies and the concave shape of their paratope
restrict the access to clefts and crypts of proteins, where often e.g.
enzymatic active sites are located [34], while artificial binding
proteins can bind such hidden epitopes [35]. In this study, an
artificial binding protein based on the scaffold ubiquitin F45W was
selected against TNF-alpha and its binding behavior towards the
target protein was characterized. In order to create a new species
of artificial binding molecules an already known binding site on
the scaffold was modified to obtain new binding properties. Such a
strategy proved to be successful for a range of previously presented
scaffolds [5,36]. In contrast to other artificial binding proteins
utilizing loop or alpha-helical structures for the creation of binding
surfaces, the technology applied here focuses particularly on the
use of beta-sheets for this purpose.
According to these premises, six amino acid positions in the
ubiquitin F45W were selected for randomization. From the
resulting library the variant 10F, binding to the target protein
TNF-alpha, was selected by ribosome display. Interestingly, in
addition to the six expected substitutions (K6F, L8Y, R42A, I44E,
H68P, V70F) two deletions (D58 & Y59) and one additional
substitution (K29R) were found. The deletions were shown to be a
Figure 4. NMR analysis of the titration of 10F with TNF-alpha.
1H-
15N fHSQC spectra of
15N-labeled ubiquitin variant 10F in presence
of increasing concentration of unlabeled TNF-alpha were recorded in
PBS, 1 mM EDTA pH 7.4 with 0.05% Tween-20. The relative intensity
decrease of two amid resonances was plotted against molar ratio of
both proteins. As determined by the intersection point of the linear fits
of the initial part and the plateau part of the curve 2.8860.18 TNF-alpha
monomers are bound per 10F molecule.
doi:10.1371/journal.pone.0031298.g004
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variant 10FDY with the re-inserted amino acids. For the additional
substitution K29R, we do not expect a target-specific interaction
because of its position and conservative character. The selected
variant 10F specifically binds its target protein TNF-alpha with a
KD of 0.1860.05 mM, an affinity which is two to three orders of
magnitude higher than most interactions of ubiquitin with
ubiquitin-binding domains [15,16].
A new binding mode
The data from isothermal titration calorimetry showed an
exothermic binding reaction and also indicated the binding of one
10F molecule to one TNF-alpha trimer, which constitutes the
bioactive TNF species [37]. The 1:3 stoichiometry was confirmed
by analytical ultracentrifugation and NMR spectroscopy. Binding
of more than one 10F molecule per TNF-alpha trimer was not
observed, which excludes the binding to a single monomer of
TNF-alpha. This contrasts the findings for the clinically approved
anti-TNF-alpha antibody infliximab [38] and other monoclonal
antibodies [39]. These bind both the trimer and the monomer
species of TNF-alpha and thus show a 1:1 stoichiometry. Also,
binding proteins based on various alternative scaffolds, e.g.
affibodies [9] and tetranectins [4], capable of recognizing the
TNF-alpha trimer, show binding stoichiometries of 1:1 per TNF-
alpha monomer. Even TNF-receptors, recognizing exclusively the
trimeric form, exhibit a 1:1 stoichiometry as their epitope is
presented three times by the trimer. This strongly indicates the
recognition of a different, trimer-based epitope by the 10F
molecule. According to our knowledge, such a binding mode to
TNF-alpha has never been observed for protein-based binders
before. A binding mode similar to small molecule-based inhibitors
Figure 6. Circular dichroism analysis of ubiquitin variants. The
far-UV CD spectra of the native proteins 10F (open circles), ubiquitin
F45W (open triangles), and 10FDY (open squares) were recorded in
10 mM KH2PO4 pH 7.4 at 20uC. For analysis of denatured proteins
(closed symbols, 10FDY not shown), samples were measured in 6 M
guanidine hydrochloride. All spectra are buffer corrected.
doi:10.1371/journal.pone.0031298.g006
Figure 5. Size exclusion chromatography (SEC) of the complex
of TNF-alpha and the ubiquitin variant 10F. (A) SEC in presence of
detergent Tween-20. Samples of fluorescein-labeled 10F (10 mM), TNF-
alpha (60 mM), and a mixture of both, were pre-incubated for 10 min at
4uC and loaded on a Superose 12 size-exclusion column. Experiments
were performed with sample and running buffer, both containing
0.05% (v/v) Tween-20, and detection wavelengths of 280 nm (blue line)
and 495 nm (red dashed line). Note that there is no significant shift of
the TNF-alpha elution volume when comparing the elution profiles of
TNF-alpha alone and the mixture. Fluorescein itself did not co-elute
with TNF-alpha (data not shown). (B) SEC in absence of detergent
Tween-20. For analysis of Tween-20 independent complex formation, a
detergent-free mixture of unlabeled 10F (10 mM) and TNF-alpha (60 mM)
was incubated at 4uC and aliquots were analyzed as described before
using running buffer without Tween-20. Note that the area of the 10F
peak (16.5 ml) decreases during prolonged incubation. Dashed lines
mark the borders of the fraction used for SDS-PAGE analysis. (C) SDS-
PAGE analysis of the detergent-free SEC complex fractions. Aliquots of
appropriate SEC fractions were analyzed by SDS-PAGE (4–12% gradient
gel) followed by Coomassie staining. M: Fermentas PageRuler
Unstained, 1: control TNF-alpha (2 mg), 2: control 10F (2 mg), 3: 0.17 h
preincubation, 4: 1 h, 5: 2 h*, 6: 6 h, 7: 12 h, 8: 24 h*, 9: 44 h. *To reduce
complexity chromatograms were not included in (B).
doi:10.1371/journal.pone.0031298.g005
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be excluded by fluorescence homoquenching experiments. How-
ever, a small-molecule inhibitor for the TNF family cytokine
CD40 ligand seems to show an interaction mode, comparable to
10F [41]. The CD40 ligand inhibitor binds in a crypt between the
subunits of the trimer. Maybe the low molecular mass of 10F with
9 kDa allows the artificial binding protein to access a similar crypt
in TNF-alpha, which is inaccessible for antibodies due to their
molecular mass of more than 120 kDa.
In NMR titration and SEC experiments an influence of the
detergent Tween-20 on the interaction between the selected
binder and TNF-alpha was discovered. A similar observation was
reported for DARPins [8]. The investigation of this detergent
effect showed that the ubiquitin variant 10F binds TNF-alpha
regardless of the presence or absence of Tween-20, but the
detergent accelerates the binding kinetics. Interestingly, the time
range necessary to observe complex formation of the ubiquitin
variant and TNF-alpha under detergent-free conditions coincides
quite well with the values reported for the TNF-alpha trimer
dissociation half-time in absence of detergents ranging from 4 to
20 h [40,42]. A conformational transition is known to precede the
dissociation of the trimeric molecule [40]. Such local conforma-
tional changes in TNF-alpha were observed at low Tween-20
concentrations of up to 0.1% (v/v) using
1H-NMR spectroscopy
(data not shown) and are probably necessary for binding of 10F.
From this, we suggest a binding model where Tween-20 mediates
the association event by stabilizing a particular conformational
state of the TNF-alpha trimer, which is bound by 10F.
Remarkably, this model is not in contradiction to the successful
competition of the interaction with etanercept. The TNF-receptor
2 may bind a different conformation, which disallows binding of
10F.
Interestingly, Tween-20 sensitivity is not totally unknown for
antibodies against TNF-alpha, the reported example shows the
suppression of binding in the presence of Tween-20 [43].
However, for a variety of successful selections against TNF-alpha
with antibodies and alternative scaffolds, so far no detergent
sensitivity of the binders was reported [4,9]. In these cases in
contrast to the present study, Tween-20 was substituted by other
detergents at least during parts of the selection procedure.
Whether this avoids the selection of Tween-20-sensitive binding
molecules remains unclear, as the here presented ubiquitin variant
10F is capable of interacting with TNF-alpha in the absence of
Tween-20. Hence, a selection without Tween-20 or other
detergents, respectively, may result in binding of the same epitope.
The selected ubiquitin variant is structured and stable
The number of substitutions and the deletions in the ubiquitin-
based scaffold that yielded the TNF-binding ubiquitin variant
were supposed to influence the structure and stability compared to
ubiquitin F45W. Although such a number of substitutions – 12%
of the amino acid sequence – is likely to destroy the structure of a
protein, this particular ubiquitin variant appeared in its structural
characterization by CD and NMR spectroscopy to have typical
properties of a natively folded protein. However, differences in the
spectroscopic character were obvious. Differences in the far-UV
CD spectrum at around 224 nm in 10FDY compared to the
scaffold ubiquitin F45W may arise from the additional tyrosine
residue Y8, giving a positive signal in the CD spectrum. Such
distinctive features are well described for proteins displaying a low
Figure 7. 2D-NMR characterization of the scaffold ubiquitin F45W and the variant 10F.
1H-
15N fHSQC spectra of the scaffold ubiquitin
F45W (black, 900 mM) and its variant 10F (red, 400 mM) were acquired on an 800 MHz NMR spectrometer at 25uC. Both proteins were dissolved in PBS,
1 mM EDTA at pH 7.4. Superimposition of the spectra shows significant deviation of chemical shifts for almost all amino acids including the
conserved ones. Note, that most residues between 130 ppm and 137 ppm are aliased along the
15N-dimension.
doi:10.1371/journal.pone.0031298.g007
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istic spectrum of 10F [44,45]. In the NMR spectra, significant
differences of the individual chemical shifts were observed for both
variants 10F and 10FDY compared to the scaffold ubiquitin F45W.
From these data alone it is difficult to predict the extent of
structural rearrangements by the substitutions. Such conclusions
require a highly resolved structure obtained by NMR spectroscopy
or X-ray crystallography, which is currently in progress.
One of the advantageous properties of ubiquitin making it an
interesting scaffold is its high thermal stability of more than 90uC
[46]. In comparison, the fully reversible temperature induced
unfolding of the binder 10F followed by far-UV circular dichroism
and tryptophan fluorescence (data not shown) showed transition
midpoints at around 76uC and 69uC, respectively. The deletion of
D58 and Y59 shows a large contribution to thermal stability as
10FDY shows a 12 K increased Tm compared to 10F. Even with a
significantly decreased transition temperature compared to the
ubiquitin wildtype, 10F still fairly competes with other scaffold-
derived proteins, for example anticalins, DARPins, and gammaB-
crystallin-based binders, regarding thermal stability [3,6,11].
Conclusions
In summary, we showed a second example of creating highly
stable artificial binding proteins with a binding site on beta-sheet
structures, in addition to the gammaB-crystallin-based binders
[11]. From a library based on the scaffold ubiquitin we were able
to select a variant binding specifically to the TNF-alpha trimer.
The detergent Tween-20 mediates the interaction, but is not
required for binding. The particular epitope targeted by this new
binding mode appears to differ from those reported for TNF-
neutralizing monoclonal antibodies [47]. This unique binding
behavior underlines the potential of alternative scaffolds to obtain
artificial binding proteins targeting epitopes which might be hardly
accessible to antibodies. For the future, this offers the opportunity
to select an appropriate scaffold for distinct epitopes and targets.
Supporting Information
Figure S1 Binding of different ubiquitin variants to
TNF-alpha analyzed by ELISA. Binding of the ubiquitin
variants 10F and 10FDY (latter one derived by re-insertion of two
deleted amino acids), and the scaffold ubiquitin F45W to
immobilized TNF-alpha (150 ng per well) are depicted.
(TIF)
Figure S2
1H-
15N fHSQC spectra of ubiquitin F45W and
its variants 10F and 10FDY. Spectra were recorded with
15N-
labeled proteins dissolved in PBS, 1 mM EDTA pH 7.4. (A) Free
and TNF-alpha-bound state of the ubiquitin variant 10F.
Measurements were performed with 160 mM 10F in presence of
0.05% (v/v) Tween-20. The spectra of the free (black) and the
bound (4-fold excess of TNF-alpha trimer) state (red) were
superimposed. (B) Comparison of ubiquitin F45W and its variant
10FDY. Protein concentrations were fixed to 900 mM (ubiquitin
F45W, black) and 600 mM (10FDY, red). (C) Comparison of
ubiquitin variants 10FDY and 10F. Spectra were recorded with
600 mM 10FDY (black) and 400 mM 10F (red). Note, that in (B)
and (C) most residues between 130 ppm and 137 ppm are aliased
along the
15N-dimension and that in (A), the
15N-spectral width
was further reduced.
(TIF)
Figure S3 Determination of the molecular mass of the
TNF-alpha-10F complex. Molecular mass of fluorescein-
labeled 10F (open circles) and TNF-alpha-10F complex (closed
circles) was determined by analytical ultracentrifugation. Upper
panel: absorbance data (490 nm) were fitted to a single species
model. The fits yielded calculated molecular masses of 1161 kDa
for 10F and 6565 kDa for the complex (theoretical molecular
mass of 10F: 9.9 kDa and complex: 62.0 kDa). Lower panel:
deviation of the fits to the experimental data.
(TIF)
Figure S4 Inhibition of TNF-alpha subunit dissociation
analyzed by fluorescence homoquenching assay. The
increase in fluorescence dequenching of 100 nM fluorescein-
labeled TNF-alpha incubated with a 200-fold excess of unlabeled
TNF-alpha was used to follow subunit dissociation of TNF-alpha
trimers. After 38 min (dashed line) 5 ml 10F (595 mM), or one of
the controls PBS, 10FDY (600 mM) and etanercept (160 mM) were
added to a total volume of 155 ml.
(TIF)
Figure S5 Thermal denaturation of the TNF-alpha
binding ubiquitin variant 10F. By following the circular
dichroism signal at 200 nm, we measured the thermal unfolding
and refolding of the ubiquitin variant 10F in 10 mM KH2PO4
pH 7.0. Tm values of 75.960.2uC for unfolding and 72.460.2uC
for refolding were determined. Ubiquitin F45W and 10FDY were
not denatured completely under the applied conditions (data not
shown). In corresponding fluorescence measurements in PBS,
1 mM EDTA at pH 7.4 – probing the tertiary structure of 10F
and 10FDY by intrinsic tryptophan fluorescence – unfolding Tm
values of 69.060.1uC (10F) and 81.160.2uC (10FDY) were found
(data not shown). The thermal stability of ubiquitin F45W allowed
no complete denaturation under the used conditions (Tm above
90uC).
(TIF)
Methods S1 Additional methods.
(PDF)
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